EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE )

Jonathan I Silverberg iD, Robert Bissonnette iD, Leon Kircik, Dedee F Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, Emma Guttman-Yassky iD

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.18914 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Jonathan I Silverberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Arena Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Etrasimod is an oral, selective, sphingosine 1‐phosphate (S1P) receptor 1,4,5 modulator in development for immune‐mediated inflammatory disorders. Efficacy and safety of orally administered S1P receptor modulation in atopic dermatitis (AD) have not yet been examined.

Objective

To assess the efficacy and safety of etrasimod monotherapy in adults with moderate‐to‐severe AD.

Methods

In this phase 2, randomized, double‐blind, placebo‐controlled trial, participants (≥18 years) with moderate‐to‐severe AD defined as baseline validated Investigator's Global Assessment (vIGA‐AD) score ≥ 3, Eczema Area and Severity Index (EASI) score ≥ 16, and body surface area involvement ≥10% were randomized 1:1:1 to once‐daily oral etrasimod 1 mg, 2 mg or placebo for 12 weeks. The primary outcome was percent change in EASI score from baseline at week 12, assessed in the Full Analysis Set (all randomized participants). Key secondary outcomes were achievement of a vIGA‐AD score of 0 or 1 with a ≥2‐point improvement from baseline and EASI‐75 response at Week 12. Safety was assessed during the double‐blind period.

Results

One hundred and forty participants were randomized to etrasimod 2 mg ( n = 47), 1 mg ( n = 47) or placebo ( n = 46). At Week 12, percent change in EASI score was −57.2% in the etrasimod 2‐mg group versus −48.4% in the placebo group ( p = 0.18). A significantly greater proportion of participants receiving etrasimod 2 mg achieved vIGA‐AD scores of 0 or 1 with a ≥2‐point improvement at Week 12 versus placebo (29.8% vs. 13.0%; p = 0.045); however, EASI‐75 response was not statistically significant versus placebo. Treatment‐emergent adverse events (AEs) occurred in 59.6%, 40.4% and 47.8% of participants receiving etrasimod 2 mg, 1 mg and placebo, respectively. There were no serious AEs or deaths.

Conclusions

The primary outcome was not met, although efficacy was observed for etrasimod 2 mg on several clinician‐ and patient‐assessed measures, and both 1‐ and 2‐mg doses were well tolerated, warranting further clinical investigation in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultHumansSphingosine-1-Phosphate ReceptorsTreatment OutcomeSeverity of Illness IndexDouble-Blind MethodAcetatesIndoles

Substanzen

Sphingosine-1-Phosphate ReceptorsetrasimodAcetatesIndoles

Autor:innen und Institutionen

  • Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Innovaderm Research, Montreal, Quebec, Canada.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Indiana University Medical Center, Indianapolis, Indiana, USA.
  • Physicians Skin Care, Louisville, Kentucky, USA.
  • DermResearch, PLLC, Louisville, Kentucky, USA.

ORCID-Profile: Jonathan I Silverberg, Robert Bissonnette, Emma Guttman-Yassky

Förderung

  • Arena Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc

Zitieren

APA

Silverberg, J. I., Bissonnette, R., Kircik, L., Murrell, D. F., Selfridge, A., Liu, K., Ahluwalia, G., & Guttman-Yassky, E. (2023). Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE ). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18914

Vancouver

Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K, et al. Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE ). Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18914

BibTeX
@article{Silverberg2023,
  author = {Silverberg, Jonathan I and Bissonnette, Robert and Kircik, Leon and Murrell, Dedee F and Selfridge, Andrew and Liu, Kris and Ahluwalia, Gurpreet and Guttman-Yassky, Emma},
  title = {Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE )},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.18914}
}
Kostenlos starten →